Faculty of Medicine, Vilnius University, M.K. Ciurlionio Str. 21, LT-03101 Vilnius, Lithuania.
Clinic of Obstetrics and Gynaecology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Santariskiu Str. 2, LT-03101 Vilnius, Lithuania.
Medicina (Kaunas). 2023 Apr 17;59(4):777. doi: 10.3390/medicina59040777.
: Cervical cancer is the fourth most common cancer in women globally. As survival rates gradually increase, it becomes necessary to assess the quality of life (QoL) after treatment. It is known that different treatment modalities have different effects on QoL. Therefore, we aimed to evaluate the QoL of cervical cancer survivors (CCSs) treated with concurrent chemoradiotherapy (CCRT). : A cross-sectional monocentric study, conducted in Vilnius university hospital Santaros klinikos between November 2018 and November 2022, included 20 women, who were interviewed once using the European Organization for Research and Treatment of Cancer (EORTC)-designed Quality-of-Life questionnaire cervical cancer module (QLQ-CX24). The sociodemographic and clinical data as well as the results of the questionnaire are presented in mean, standard deviation and percentages. The QoL scores were compared between different age and stage groups using the Mann-Whitney U test. : Twenty participants, aged from 27 to 55 years, with a mean age of 44 years (SD = 7.6) participated in the study. All the participants were CCSs with an International Federation of Gynecology and Obstetrics (FIGO) stage from IB to IIIB and all of them were treated with CCRT. The symptom experience was relatively low and revealed a good result (21.8, SD = 10.2). Mean scores on body image, sexual/vaginal functioning, menopausal symptoms and sexual worry scales indicated moderate functioning and a moderate level of some of the cervical cancer specific symptoms after CCRT. Sexual activity and sexual enjoyment of the CCSs were low (11.7 (SD = 16.3), 14.3 (SD = 17.8), respectively). : Cervical cancer survivors report a relatively good quality of life regarding symptom experience; however, women following concurrent chemoradiotherapy tend not to be sexually active and rarely feel sexual enjoyment. In addition, this treatment modality negatively affects a woman's body image and self-perception as a woman.
宫颈癌是全球女性中第四常见的癌症。随着存活率的逐渐提高,评估治疗后生活质量(QoL)变得尤为重要。不同的治疗方式对 QoL 的影响不同。因此,我们旨在评估接受同期放化疗(CCRT)治疗的宫颈癌幸存者(CCS)的 QoL。
这是一项在 2018 年 11 月至 2022 年 11 月期间在维尔纽斯大学 Santaros 临床医院进行的横断面单中心研究,共纳入 20 名女性,她们通过欧洲癌症研究与治疗组织(EORTC)设计的生活质量问卷宫颈癌模块(QLQ-CX24)接受了一次访谈。研究结果以平均值、标准差和百分比的形式呈现。使用 Mann-Whitney U 检验比较了不同年龄和阶段组之间的 QoL 评分。
20 名参与者的年龄在 27 至 55 岁之间,平均年龄为 44 岁(SD = 7.6)。所有参与者均为 CCS,国际妇产科联合会(FIGO)分期从 IB 期到 IIIB 期,均接受 CCRT 治疗。症状体验相对较低,结果良好(21.8,SD = 10.2)。身体形象、性/阴道功能、绝经症状和性担忧量表的平均得分表明,CCRT 后,这些与宫颈癌相关的症状中有一些表现出中等功能和中等程度。CCS 的性活动和性享受较低(分别为 11.7(SD = 16.3)和 14.3(SD = 17.8))。
宫颈癌幸存者报告了相对较好的生活质量,尤其是在症状体验方面;然而,接受同期放化疗的女性往往没有性活跃,很少感到性享受。此外,这种治疗方式还会对女性的身体形象和女性自我认知产生负面影响。